Frontiers in Clinical Drug Research - Alzheimer Disorders: Volume 6
()
About this ebook
Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders.
Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimer’s Disease research.
The sixth volume of this series features chapters covering critical discussions on AD management and new therapies. The topics reviewed in this volume include:
- treatment of brain inflammation in Alzheimer’s disease with traditional medicine
- stem cell strategies for the modeling and therapy of Alzheimer’s disease
- retinal neurodegeneration in Alzheimer’s disease
- biological mass spectrometry for diagnosis of Alzheimer's disease
…and more.
Related to Frontiers in Clinical Drug Research - Alzheimer Disorders
Titles in the series (4)
Frontiers in Clinical Drug Research - Alzheimer Disorders: Volume 5 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Alzheimer Disorders: Volume 6 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Alzheimer Disorders: Volume 7 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Alzheimer Disorders Volume 8 Rating: 0 out of 5 stars0 ratings
Related ebooks
Frontiers in CNS Drug Discovery: Volume 3 Rating: 0 out of 5 stars0 ratingsTopics in Anti-Cancer Research: Volume 8 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Central Nervous System: Volume 1 Rating: 0 out of 5 stars0 ratingsA Paradigm Shift to Prevent and Treat Alzheimer's Disease: From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols Rating: 0 out of 5 stars0 ratingsDrug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease Rating: 0 out of 5 stars0 ratingsBiochemical Actions of Hormones V3 Rating: 0 out of 5 stars0 ratingsDiseases of the Nervous System Rating: 0 out of 5 stars0 ratingsSex Differences in Cardiovascular Physiology and Pathophysiology Rating: 0 out of 5 stars0 ratingsLaboratory Investigation of Endocrine Disorders Rating: 0 out of 5 stars0 ratingsHuman Blood Plasma Proteins: Structure and Function Rating: 0 out of 5 stars0 ratingsPituitary Disorders: Diagnosis and Management Rating: 0 out of 5 stars0 ratingsNanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer Rating: 0 out of 5 stars0 ratingsNeuroinflammation in Vascular Dementia Rating: 0 out of 5 stars0 ratingsPharmacology of Antihypertensive Drugs Rating: 3 out of 5 stars3/5The Collapse of Darwinism: How Medical Science Proves Evolution by Natural Selection Is a Failed Theory Rating: 0 out of 5 stars0 ratingsBrain Evangelists: How Psychiatry Has Convinced Us to Believe in Its Far-Fetched Science and Dubious Treatments Rating: 0 out of 5 stars0 ratingsAn Innovative Approach to Understanding and Treating Cancer: Targeting pH: From Etiopathogenesis to New Therapeutic Avenues Rating: 0 out of 5 stars0 ratingsAlternative Health Care Rating: 0 out of 5 stars0 ratingsNeurocircuitry of Addiction Rating: 0 out of 5 stars0 ratingsMS In The Raw: An inspirational book for people living with MS Rating: 0 out of 5 stars0 ratingsNanobiomaterials in Cancer Therapy: Applications of Nanobiomaterials Rating: 0 out of 5 stars0 ratingsThe Home Medical Library, Volume I (of VI) Rating: 0 out of 5 stars0 ratingsOmicron & Delta Viruses Infection Long Hauler Symptoms Diagnosis Patients and Physicians Management Handbook Rating: 0 out of 5 stars0 ratingsArtemisinin-Based and Other Antimalarials: Detailed Account of Studies by Chinese Scientists Who Discovered and Developed Them Rating: 0 out of 5 stars0 ratingsAlzheimer's Disease: A Holistic Approach Rating: 0 out of 5 stars0 ratingsMolecular Targets in Protein Misfolding and Neurodegenerative Disease Rating: 0 out of 5 stars0 ratingsBioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases: Bioactive Food in Chronic Disease States Rating: 0 out of 5 stars0 ratingsOxidative Stress and Antioxidant Protection: The Science of Free Radical Biology and Disease Rating: 0 out of 5 stars0 ratings
Chemistry For You
Chemistry For Dummies Rating: 4 out of 5 stars4/5The Secrets of Alchemy Rating: 4 out of 5 stars4/5Organic Chemistry I For Dummies Rating: 5 out of 5 stars5/5Toxic Legacy: How the Weedkiller Glyphosate Is Destroying Our Health and the Environment Rating: 5 out of 5 stars5/5Half Lives: The Unlikely History of Radium Rating: 4 out of 5 stars4/5Dr. Joe & What You Didn't Know: 177 Fascinating Questions & Answers about the Chemistry of Everyday Life Rating: 0 out of 5 stars0 ratingsPIHKAL: A Chemical Love Story Rating: 4 out of 5 stars4/5TIHKAL: The Continuation Rating: 4 out of 5 stars4/5Organic Chemistry I Essentials Rating: 4 out of 5 stars4/5Painless Chemistry Rating: 0 out of 5 stars0 ratingsGeneral Chemistry Rating: 4 out of 5 stars4/5Monkeys, Myths, and Molecules: Separating Fact from Fiction in the Science of Everyday Life Rating: 4 out of 5 stars4/5Mendeleyev's Dream Rating: 4 out of 5 stars4/5AP Chemistry Flashcards, Fourth Edition: Up-to-Date Review and Practice Rating: 0 out of 5 stars0 ratingsThe Chemistry Book: From Gunpowder to Graphene, 250 Milestones in the History of Chemistry Rating: 5 out of 5 stars5/5Stuff Matters: Exploring the Marvelous Materials That Shape Our Man-Made World Rating: 4 out of 5 stars4/5MCAT General Chemistry Review 2024-2025: Online + Book Rating: 0 out of 5 stars0 ratingsChemistry: a QuickStudy Laminated Reference Guide Rating: 5 out of 5 stars5/5The Nature of Drugs Vol. 1: History, Pharmacology, and Social Impact Rating: 5 out of 5 stars5/5Chemistry: Concepts and Problems, A Self-Teaching Guide Rating: 5 out of 5 stars5/5Taste: Surprising Stories and Science About Why Food Tastes Good Rating: 3 out of 5 stars3/5College Chemistry Rating: 4 out of 5 stars4/5Chemistry Workbook For Dummies with Online Practice Rating: 0 out of 5 stars0 ratingsCollege Biology Rating: 4 out of 5 stars4/5AP Chemistry Test Prep Review--Exambusters Flash Cards: AP Exam Study Guide Rating: 0 out of 5 stars0 ratingsWhy Is Milk White?: & 200 Other Curious Chemistry Questions Rating: 5 out of 5 stars5/5Catch Up Chemistry, second edition: For the Life and Medical Sciences Rating: 5 out of 5 stars5/5A to Z Magic Mushrooms Making Your Own for Total Beginners Rating: 0 out of 5 stars0 ratings
Reviews for Frontiers in Clinical Drug Research - Alzheimer Disorders
0 ratings0 reviews
Book preview
Frontiers in Clinical Drug Research - Alzheimer Disorders - Bentham Science Publishers
Table of Contents
Welcome
Table Of Contents
Title Page
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
Usage Rules:
Disclaimer:
Limitation of Liability:
General:
PREFACE
List of Contributors
The Treatment of Brain Inflammation in Alzheimer’s Disease. Can Traditional Medicines Help?
Abstract
INTRODUCTION
Anti-inflammatory Agents in AD
Risk Factors for Developing AD
Prevention of AD
Ceramide and AD
The Blood Brain Barrier and AD
Visfatin and AD
Traditional Plant Medicines for AD
The Modern Approach to Curing AD
Concluding Remarks
CONFLICT OF INTEREST
ACKNOWLEDGEMENT
References
Stem Cell Strategies for the Modeling and Therapy of Alzheimer’s Disease
Abstract
1. INTRODUCTION
2. NEUROPATHOLOGY OF AD: KEYS TO DRUG DISCOVERY AND ANIMAL MODELS
The β-amyloid Hypothesis of AD
The Hyper-phosphorylated Tau Protein Hypothesis of AD
The cholinergic hypothesis of AD
2.1. Drug Discovery of AD
2.1.1. Treatment of Amyloid Pathology
2.1.2. Treatment of Tau Pathology
2.1.3. Treatment of Synaptic Dysfunction
2.1.4. Neurotrophic Factors (NTFs)
2.1.5. Cell Transplantation
2.2. Animal Models of AD
2.2.1. Transgenic Animal Models of AD
2.2.2. Selective Cholinergic Lesion Animal Models of AD
3. STEM CELLS AS USEFUL TOOLS FOR CELL TRANSPLANTATION, DRUG DISCOVERY AND AD MODELING
3.1. Neural Stem/Progenitor Cells (NP/SCs)
3.2. Mesenchymal Stem Cells (MSCs)
3.3. Embryonic Stem Cells (ESCs)
3.4. Induced Pluripotent Stem Cells (IPSCs)
3.5. In Situ Generation of Neurons in the Brain
3.6. Modeling and Therapy of AD with Genome Editing
4. PERSPECTIVES
ABBREVIATIONS
CONFLICT OF INTEREST
ACKNOWLEDGEMENT
References
Retinal Neurodegeneration in Alzheimer’s Disease
Abstract
INTRODUCTION
THE RETINA – AN INTEGRAL PART OF THE BRAIN
VISUAL CHANGES IN AD
Visual Abnormalities
Pupil Abnormalities
RETINAL CHANGES IN AD
Retinal Histopathologic Abnormalities
Retinal in vivo Abnormalities
Retinal Nerve Abnormalities
Retinal Vasculature Abnormalities
Retinal Cellular Abnormalities – RGC Apoptosis
NON-RETINAL OCULAR CHANGES IN AD
AD-RELATED CHANGES IN RETINAL DISEASES
AD-related Changes in Glaucoma
AD-related Changes in AMD
TARGETING OF AMYLOID-ß IN TREATMENT OF GLAUCOMA AND AMD
CONCLUSION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Pathophysiology of Alzheimer Disease: Current Drug Therapy
Abstract
INTRODUCTION
PATHOPHYSIOLOGY OF ALZHEIMER’S DISEASE
HYPERTENSION AND ALZHEIMER’S DISEASE
ROLE OF RENIN ANGIOTENSIN SYSTEM (RAS) IN ALZHEIMER’S DISEASE
GENETIC POLYMORPHISM AND AD
TREATMENTS FOR ALZHEIMER’S DISEASE
HERBAL DRUGS FOR THE TREATMENT OF AD
CONCLUSION
ABBREVIATIONS:
CONFLICT OF INTEREST
Acknowledgements
REFERENCES
Biological Mass Spectrometry for Diagnosis of Alzheimer's Disease
Abstract
INTRODUCTION
Requirements of Alzheimer's Disease Diagnosis
Application of Mass Spectrometry for Alzheimer's Disease
Imaging Mass Spectrometry for Alzheimer's Disease
Advantages and disadvantages of Mass Spectrometry
CONCLUSION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
The Structure-Activity Relationship of Melanin as a Source of Energy Defines the Role of Glucose to Biomass Supply Only, Implications in the Context of the Failing Brain
Abstract
INTRODUCTION
Basal Brain Energy Metabolism
The Role of Pyridine Nucleotides and the Abnormal Expression of Genes
Oxidative Stress
Remarks and Conclusion
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Neuro-protective Properties of the Fungus Isaria japonica: Evidence from a Mouse Model of Aged-related Degeneration
Abstract
INTRODUCTION
IJE Improves Nerve Function in Aged Mouse Brain
1. Neuroprotective Effects of IJE
2. Histochemical Observation
3. Assessments of Acute and Sub-acute Toxicity
NMR Analyses in the I. Japonica Extract
1. Chemical Component of I. Japonica
1.1. Living Substances
2. Biologically Active Substances
2.1. Cyclic Peptides
2.2. Isariotins and Its Related Natural Products
2.3. Cyclic Terpenoids
2.4. Others
3. NMR and Mass Study of Water Extract of I. Japonica
Visualization of the Physiological and Pathological Alterations in the Central Nervous System using MRI and MRS
1. Fine Imaging Using Ultra-high Field MRI
2. Magnetic Resonance Spectroscopy
3. Brain Temperature Estimation Using MRS
CONCLUDING REMARKS
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Frontiers in Clinical Drug Research -
Alzheimer Disorders
(Volume 6)
Edited by:
Atta-ur-Rahman, FRS
Kings College,University of Cambridge,Cambridge,UK
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (Work
). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.
Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided as is
without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.
PREFACE
The book series, "Frontiers in Clinical Drug Research – Alzheimer Disorders", is intended to present the important advancements in the field in the form of cutting edge reviews written by experts. Volume 6 of this eBook series is a compilation of seven well written chapters contributed by prominent researchers in the field. It includes the treatment of brain inflammation, stem cell strategies, retinal neurodegeneration, pathophysiology of Alzheimer disease, and a number of other related areas.
Chapter 1 by Adams discusses the use of plant medicines as an alternative treatment to decrease the progression of Alzheimer’s disease (AD). In chapter 2, Haigang Gu describes the recent progress of stem cell strategies for AD modeling and therapy. Cordeiro et al. in chapter 3 focus on the retinal neurodegeneration in AD. The pathological similarities between AD and eye diseases are also discussed. In Chapter 4, Gupta & Jhawat highlight the pathophysiology of Alzheimer disease with respect to the current drug therapy.
In chapter 5, Abdelhamid and Wu present the use of biological mass spectrometry for the diagnosis of Alzheimer’s disease. This review also highlights the recent developments in disease diagnosis using mass spectrometry. Chapter 6 by Herrera emphasizes the structure-activity relationship of melanin as a source of energy. The last chapter by Suzuki et al., discusses the neuro-protective properties of the fungus Isaria japonica (IJ). The results showed that products derived from IJ may prevent or decrease the impact of dementia, especially AD.
The 6th volume of this book series represents the results of a huge amount of work by many eminent researchers. I am grateful to the authors for their excellent contributions. I would also like to express my gratitude to the editorial staff of Bentham Science Publishers, particularly Mr. Mahmood Alam (Director Publication), Mr. Shehzad Naqvi (Senior Manager Publications) and Ms. Fariya Zulfiqar (Assistant Manager Publications) for their hard work and persistent efforts.
Prof. Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK
List of Contributors
The Treatment of Brain Inflammation in Alzheimer’s Disease. Can Traditional Medicines Help?
James David Adams*
School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90089, USA
Abstract
The blood brain barrier degenerates in many people as they age. This degeneration can lead to inflammation, amyloid accumulation, neuron loss, tangle accumulation and dementia. Damage to the blood brain barrier may involve oxygen radical production through a visfatin mediated mechanism. Several plant medicines have been traditionally used to decrease the progression of Alzheimer’s disease. Antioxidant mechanisms of action have been described for these medicines that may protect the blood brain barrier. These plant medicines provide alternative treatments for Alzheimer’s disease.
Keywords: Alzheimer’s disease, Anti-inflammatory prevention, Plant medicines.
* Corresponding author James David Adams: School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90089, USA; Tel: 323-442-1362; Fax: 323-442-1681; E-mail: jadams@usc.edu
INTRODUCTION
Alzheimer’s disease (AD) involves neurodegeneration induced by amyloidβ. This neurodegeneration results in loss of neurons, plaque and tangle formation and ultimately in dementia. Many AD patients are treated with acetylcholinesterase inhibitors to slow the progression of mild AD. Eventually, most AD patients die from pneumonia and not neurodegeneration.
The current consensus is that AD is caused by amyloidβ toxicity in the brain [1]. It is clear that extracellular amyloidβ is toxic to neurons. Amyloidβ aggregates into fibrils, sheets and plaques. Some intermediate amyloid protein aggregates in the plaque formation process are toxic to neurons.
The role of inflammation in the pathophysiology of AD is well established [1]. Inflammation in AD can be secondary to amyloidβ accumulation. In other words, amyloidβ causes inflammation in the brain. Inflammation can also occur early in
the disease process and initiate amyloidβ accumulation and AD pathology [2]. This inflammation involves microglial cells, astrocytes, perivascular macrophages and monocytes that infiltrate into the brain [2]. There are a number of different inflammatory molecules that are produced in the brain in this inflammatory process and as a consequence of amyloidβ production including chemokines, complement molecules, cytokines, inflammatory and acute phase proteins, cyclooxygenase-2, and free radicals [2-5].
Tau phosphorylation leading to tangle formation may occur as the result of amyloidβ oligomer toxicity [1]. Microglial and astrocytic activation are also involved in alteration of tau phosphorylation [1]. Neurofibrillary tangles are frequently found in AD brains.
The question that remains unanswered is why does amyloidβ production increase in the brains of people who will develop AD? This question can be avoided by claiming that 100% of people will develop AD if they live long enough. In other words, amyloidβ accumulation is a natural process in the brain that cannot be avoided. However, many very old people do not develop AD.
Anti-inflammatory Agents in AD
Several epidemiological studies have examined the use of anti-inflammatory drugs in patients and have found that the use of these drugs may decrease the induction of AD. These studies have been critically reviewed [2, 5, 6]. The use of indomethacin was reported to slow the progression of AD [7]. This finding was later disputed [8]. Patients suffering from arthritis have a decreased risk of developing AD, perhaps because of their use of anti-inflammatory agents [9]. Several other reports have failed to show a protective effect of anti-inflammatory agents in the progression or development of AD. In addition, several attempts to slow the progression of AD with various anti-inflammatory drugs have failed to show an effect. It must be remembered that oral nonsteroidal anti-inflammatory agents (NSAIDs) are very toxic, especially to the elderly. NSAIDs have effects on prostaglandins, lipoxins, resolvins, thromboxanes and other lipid metabolites. NSAIDs cause strokes, heart attacks, kidney damage and ulcers. They cause 42,000 or more deaths in the US every year. NSAIDs should be avoided in trials that hope to delay the progression of AD. Steroids damage the hippocampus and should also be avoided [10]. Perhaps the choice of anti-inflammatory agent has been inappropriate so far. In addition, the doses chosen may have been inappropriate in past studies. The doses chosen were probably too high and induced too much toxicity.
Risk Factors for Developing AD
If all people get AD with age, then the only risk factor for developing AD should be age. However, there are other risk factors that increase the chance of developing AD. The risk factors for developing AD are age, head trauma, high blood pressure, high blood cholesterol, diabetes, cardiovascular disease, atrial fibrillation, apolipoprotein E4, thrombosis, peripheral inflammatory factors, decreased muscle mass and high alcohol consumption [11-13]. Women are more likely to develop AD than men [11-13]. Brain trauma can cause gliosis, inflammation and deleterious changes to the brain that may be important in AD. Peripheral inflammatory factors cause high blood pressure, high blood cholesterol, type 2 diabetes, cardiovascular disease, atrial fibrillation and thrombosis [14]. These peripheral inflammatory factors include adipokines made in visceral and ectopic fat that are released into the blood. Inflammatory adipokines include visfatin, leptin, resistin, tumor necrosis factor α, IL-6 and others.
As people age, visceral and ectopic fat deposits develop. Toxic lifestyles, including lack of exercise and over eating, cause fat accumulation. Ectopic fat is fat that surrounds arteries, infiltrates muscles and other sites. Visceral fat accumulates in the peritoneal cavity. Therefore risk factors for AD are probably high blood levels of inflammatory adipokines released by visceral and ectopic fat. Obesity has increased greatly since the 1980s as reported by the Centers for Disease Control (www.cdc.gov). The incidence of AD has also increased greatly since 1980, in parallel with the increase in visceral obesity [15]. According to the Centers for Disease Control, among the entire US population, 93,500 people died while affected with AD in 2014. The entire US population, age adjusted death rate from AD increased by 39% from 2000 through 2010.
Several studies found the incidence of AD decreased over the last 25 years or more by about 25% [16-19], in spite of the increases in obesity and type 2 diabetes. These studies were done in selected populations and point to better education and better treatment of heart disease as ways to prevent AD. This indicates that patients who are educated enough about risk factors for AD to seek out better health care and other healthy lifestyle practices have a decreased risk. Weight reduction can be part of a healthy lifestyle. All of these studies advise that patients who practice healthy lifestyles have a decreased risk of developing AD. Is the incidence of AD actually decreasing in the US? The answer is clearly that the incidence of AD is increasing in the total US population.
Apolipoprotein E4 transports lipids inside the brain, including cholesterol and triglycerides. When triglycerides accumulate, the alternative fat ceramide is made in greater amounts. Apolipoprotein E4 is made in astrocytes and transports lipids to neurons by interacting with receptors in the low density lipoprotein receptor family. Since apolipoprotein E4 is a risk factor for developing AD, lipids are probably important in the mechanism of induction of AD.
Muscles produce myokines such as adiponectin, irisin, IL-6, IL-8 and IL-15 [20]. These myokines stimulate lipolysis, decrease atherosclerosis and are anti-inflammatory. Muscle is also responsible for clearing some insulin and glucose from the blood. Loss of muscle tissue causes insulin levels to increase leading to insulin resistance, also known as type 2 diabetes. Loss of anti-inflammatory myokines may be important in the induction of AD.
Alcohol consumption leads to visceral fat and ectopic fat accumulation since alcohol activates sterol regulatory element